Development of a new ultra sensitive real-time PCR assay (ultra sensitive RTQ-PCR) for the quantification of HBV-DNA by Paraskevis, Dimitrios et al.
METHODOLOGY Open Access
Development of a new ultra sensitive real-time
PCR assay (ultra sensitive RTQ-PCR) for the
quantification of HBV-DNA
Dimitrios Paraskevis1*, Apostolos Beloukas1, Catherine Haida1, Antigoni Katsoulidou1, Zisis Moschidis1,
Helen Hatzitheodorou1, Agoritsa Varaklioti2, Vana Sypsa1, Angelos Hatzakis1
Abstract
Background: Improved sensitivity of HBV-DNA tests is of critical importance for the management of HBV infection.
Our aim was to develop and assess a new ultra sensitive in-house real-time PCR assay for HBV-DNA quantification
(ultra sensitive RTQ-PCR).
Results: Previously used HBV-DNA standards were calibrated against the WHO 1st International Standard for HBV-
DNA (OptiQuant® HBV-DNA Quantification Panel, Accrometrix Europe B.V.). The 95% and 50% HBV-DNA detection
end-point of the assay were 22.2 and 8.4 IU/mL. According to the calibration results, 1 IU/mL equals 2.8 copies/mL.
Importantly the clinical performance of the ultra sensitive real-time PCR was tested similar (67%) to the Procleix
Ultrio discriminatory HBV test (dHBV) (70%) in low-titer samples from patients with occult Hepatitis B. Finally, in the
comparison of ultra sensitive RTQ-PCR with the commercially available COBAS TaqMan HBV Test, the in-house
assay identified 94.7% of the 94 specimens as positive versus 90.4% identified by TaqMan, while the quantitative
results that were positive by both assay were strongly correlated (r = 0.979).
Conclusions: We report a new ultra sensitive real time PCR molecular beacon based assay with remarkable
analytical and clinical sensitivity, calibrated against the WHO 1st International standard.
Background
Chronic hepatitis B virus (HBV) infection can be
assessed by evaluating clinical features and biochemical,
virologic, and histologic parameters. Knowledge of
HBV-DNA viral load is useful for predicting disease
prognosis, determining infectivity, evaluating indications
for treatment, assessing response to treatment identify-
ing emergence of resistance, and diagnosing occult HBV
infection [1-5].
There are several commercially available HBV-DNA
tests. The oldest versions suffered from poor sensitivity
(approximately 5·105 copies/mL) and a narrow dynamic
range of HBV-DNA quantification (~3-4 log10), while
the current limit of detection of the newer assays is
lower than 50 IU/mL with a dynamic range of approxi-
mately 8 log10 [6-13]. Additionally several in-house
quantitative assays for HBV-DNA have been developed,
based mostly on real-time PCR methodology, showing a
remarkable sensitivity and a wide linear range for quan-
tification [6,7,11-14].
Importantly, improved sensitivity of HBV-DNA tests is
of critical importance for the management of HBV
infection as well as for the diagnosis of occult HBV
infection [HBsAg(-), HBV-DNA(+)] [15].
The objective of this study was to develop a new ultra
sensitive real-time PCR assay based on the knowhow of
the existing real-time PCR assay for the quantification
of the HBV-DNA [12] and, also, to assess its perfor-
mance characteristics.
Methods
DNA extraction
The HBV-DNA was extracted from 0.5 mL of serum/
plasma using the QIAamp UltraSens Virus Kit (QIA-
GEN Inc., Valencia CA) and the DNA was eluted in 60
μl of elution buffer. For each ultra sensitive RTQ-PCR
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HBV-DNA quantification measurement, a positive HBV-
DNA sample with known HBV-DNA titer (~104 IU/mL)
and one negative control (negative human plasma) (Pro-
cleix® Negative Calibrator, Chiron/GenProbe, CA) were
extracted additional to the unknown samples.
Ultra Sensitive RTQ-PCR
The assay was carried out into a LightCycler® 2.0 appara-
tus. The reaction mixture contained 1× reaction buffer
(LightCycler DNA Master HybProbe; Roche Applied
Science. Germany), 5 mM MgCl2, 0.5 μM primer hbv305
(sense) 5’-GCCAAAATTCGCAGTCCC-3’, 0.5 μM pri-
mer hbv460 (antisense) 5’-GATAGTCCAGAAGAAC-
CAACAAGAAG-3’, 0.4 μM molecular beacon 5’-CG
CGCGATGAGGCATAGCAGCAGGATGAAGAACG
CGCG-3’ labelled with FAM and Dabcyl at the 5’ and 3’
ends, respectively, Taq DNA polymerase, dNTP mix
(with dUTP instead of dTTP), and 1 U of uracil-DNA
glycosylase (Roche Applied Science. Germany). The
amplification profile was as follows: One cycle of initial
denaturation (95°C for 10 min) followed by 40 cycles of
amplification at 95°C for 0 sec, 55°C for 10 sec, and at
72°C for 8 sec. The final reaction volume was 60 μl con-
taining 30 μl of extracted viral DNA.
Analytical Sensitivity of the ultra sensitive RTQ-PCR
The sensitivity together with the 95% and 50% HBV-
DNA detection limits of the assay were estimated by
using the WHO 1st International Standard for HBV-
DNA (OptiQuant® HBV-DNA Quantification Panel,
Accrometrix Europe B.V.), tested in 8 replicas. We per-
formed serial dilutions with human negative plasma
(Procleix® Negative Calibrator, Chiron/GenProbe, CA) of
the WHO standard at final concentrations of 100, 50,
25, 10 and 5 IU/mL. The 95% and 50% HBV-DNA
detection limits were calculated by probit analysis (8
replicas).
Assessment in a low titter HBV-DNA panel
The clinical performance of the assay was tested on 27
samples drawn from 22 individuals with occult Hepatitis
B (HBs Ag negative, consistently reactive by multiplex
Procleix Ultrio HIV-1/HCV/HBV and Procleix Ultrio
discriminatory HIV and HCV negative) screened with
the discriminatory HBV assay (dHBV) (Chiron/GenP-
robe, Emeryville/San Diego, CA).
Calibration of the HBV-DNA values copies/ml vs IU/ml
The calibration of the HBV-DNA values was performed
against the WHO 1st International Standard for HBV-
DNA (OptiQuant® HBV-DNA Quantification Panel,
Accrometrix Europe B.V.). Specifically, serial dilutions of
the WHO standard ranging from 2·102 to 2·106 IU/mL)
in 5 individual sample preparations were tested by the
ultra sensitive RTQ-PCR method. Based on a linear
regression, a conversion formula was calculated for the
in-house measurements (copies/mL) to the international
standard units (IU/mL).
Comparison of the ultra sensitive RTQ-PCR vs the
previous real-time PCR assay
To compare the ultra sensitive RTQ-PCR assay with the
previously reported test, HBV-DNA derived from 25
randomly selected samples was quantified using both
methods. The correlation of the HBV-DNA quantifica-
tions by using the current and the previous in-house
assay was also estimated.
Comparison of the ultra sensitive RTQ-PCR vs COBAS
TaqMan HBV Test
To compare the ultra sensitive RTQ-PCR assay with the
commercially available COBAS TaqMan HBV Test,
plasma samples collected from 94 different HBV-
infected patients were tested. The correlation of the
HBV-DNA quantifications by using the in-house and
the commercial test was also estimated.
Statistical analysis
Pearson’s correlation coefficient was used to assess the
strength of the linear association between the log10-
transformed values of the estimated (copies/mL) versus
the expected values (IU/mL) and also between HBV-
DNA quantifications using the two in house real-time
PCR assays and COBAS TaqMan as well. To compare
the quantitative results obtained for the samples found
positive by the two different methods (ultra sensitive
RTQ-PCR vs COBAS TaqMan HBV Test) the fitted
regression line was compared to the line of equality by
testing the two-tailed hypothesis of slope = 1 and the
intercept = 0.
Results
The ultra sensitive RTQ-PCR was performed in a Light-
Cycler® 2.0 apparatus using a plasmid HBV-DNA stan-
dard as described previously. We should note that the
specificity of the assay was 100% as shown previously
[12]. The differences between the newly developed
method (ultra sensitive RTQ-PCR) and the previous one
[12] were: 1) the utilization of a molecular beacon
instead of 2 hybridization probes, 2) extraction of HBV-
DNA from a larger volume of serum/plasma (0.5 versus
0.2 mL), 3) use of 30 μl instead of 10 μl extracted DNA,
4) modified RTQ-PCR conditions, and 5) all experi-
ments were performed in a LightCycler® 2.0 apparatus
because the latter shows improved performance charac-
teristics compared to LightCycler® 1.0. Moreover reac-
tion volume in LightCycler® 2.0 can be as large as 100
μL compared to 20 μL in the LighCycler® 1.0.
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Analytical sensitivity of ultra sensitive RTQ-PCR
To determine the analytical sensitivity of the ultra sensi-
tive RTQ-PCR, 5 dilutions of the WHO 1st International
Standard for HBV-DNA were tested (OptiQuant® HBV-
DNA Quantification Panel, Accrometrix Europe B.V.).
DNA concentrations above 25 IU/mL were detected on
all 8 occasions; concentrations of 10 IU/mL were tested
on 4 of 8 occasions (50%), while 5 IU/mL were detected
on 2 out of 8 occasions (25%). The 95% and 50% detec-
tion end-point of the assay were 22.2 and 8.4 IU/mL
respectively.
Performance of ultra sensitivity RTQ-PCR assay in low
titer HBV-DNA clinical samples
The performance of the assay was tested on 27 samples
collected from 22 individuals with occult Hepatitis B
(HBsAg negative, HBV-DNA consistently reactive by
Ultrio, Ultrio HIV and HCV negative). This analysis was
part of another study concerning the molecular typing
of occult Hepatitis B in blood donors across Greece
[15]. The characteristics of these patients are shown in
Table 1. These samples were selected because of the
low HBV-DNA titer. Among the 27 samples tested with
the dHBV test, 19 (70%) were found to be above the
threshold of detection, while a similar sensitivity was
observed for the ultra sensitive RTQ-PCR method (18
samples tested positive out of 27, 67%). The mean
HBV-DNA was 59.1 IU/mL (range, 10.2 to 346.7 IU/
mL). We should note, however, that the dHBV assay
was applied multiple times to 18 samples (a sample was
considered positive, if it was tested above the threshold
of detection at least once), while ultra sensitive RTQ-
PCR was performed only once. As shown in table 2, 14
samples were detectable by both methods, while 4 and
5 samples were tested positive only by ultra sensitive
RTQ-PCR and the dHBV test, respectively. These quali-
tative findings suggest that the in-house assay per-
formed equally well as the commercial test, although
the samples were tested multiple times by the latter
method.
Table 1 Epidemiological, molecular and serological features of 27 samples obtained from 22 Blood Donors with Occult
Hepatitis B Infection*
Patient ID Sample dHBV1 In-house Assay IU/mL aanti-HBc (IgM) anti-Hbs anti-HBe
Blood donor 1 1 + + 69.2 - - -
2 + + 89.1 - +
Blood donor 2 3 + - - - -
Blood donor 3 4 + - - - -
Blood donor 4 5 + + 10.2 - + -
6 + + 40.7 - + -
Blood donor 5 7 + + 25.1
8 - + 97.7 - + -
Blood donor 6 9 + + 46.8 - - +
Blood donor 7 10 + + 25.1 - + +
Blood donor 8 11 + - - - +
Blood donor 9 12 + + 47.9 - - +
Blood donor 10 13 + + 346.7 - - +
Blood donor 11 14 + + 26.9 - + -
Blood donor 12 15 - - - - +
Blood donor 13 16 + - - + -
Blood donor 14 17 + + 13.5 - + -
Blood donor 15 18 + + 27.5 - + -
Blood donor 16 19 - - - - +
Blood donor 17 20 - + 15.8 - + +
21 - - - + +
Blood donor 18 22 + + 41.7 - - +
23 - - - - +
Blood donor 19 24 - + 25.1 - + +
Blood donor 20 25 + + 91.2 - - -
Blood donor 21 26 + - - - -
Blood donor 22 27 - + 24.0 + + +
1dHBV: Procleix Ultrio discriminatory HBV test
*All subjects were HBsAg(-)/HBeAg(-)/IgG-anti-HBc(+)
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Calibration of the HBV-DNA values obtained with the
ultra sensitive RTQ-PCR against the WHO 1st International
Standard for HBV-DNA
The calibration of the in-house assay was done against
the WHO 1st International Standard for HBV-DNA
(OptiQuant® HBV-DNA Quantification Panel, Accrome-
trix Europe B.V.) DNA was extracted and HBV-DNA
was tested in 5 replicates by using the plasmid DNA as
a standard. The correlation plot of the expected (log10
HBV-DNA IU/mL) versus the estimated values by ultra
sensitive RTQ-PCR log10 HBV-DNA copies/mL) is
shown in Fig. 1. The fitted regression lines between IU/
mL and copies/mL was given by the following equation:
log10 (IU/mL) = -0.4475 + 1.0096·log10(ultra sensitive
RTQ-PCR copies/mL), suggesting that in our setting, 1
IU/mL = 2.8 copies/mL. The 95% CI for the estimated
intercept was -0.69, -0.21. The 95% CI for the estimated
slope was: 0.96, 1.06. The correlation coefficient between
the expected and the estimated values was very good r =
0.9937 (p < .001) (Fig. 1).
Comparison of the ultra sensitive RTQ-PCR with the
previous HBV-DNA test
To assess the correlation between the previous and the
new assay, we re-tested 25 previously quantified sam-
ples. The average log10 HBV-DNA was 5.38 copies/mL
(range, 2.31 to 10.51 log10 copies/mL). Importantly, the
linearity was very good between the HBV-DNA values
quantified by the two assays (r = 0.985, p < .001) over
the whole range of quantification. The fitted regression
line between the ultra sensitive RTQ-PCR and the pre-
vious test was: log10 HBV-DNA (copies/mL) with the
ultra sensitive RTQ-PCR = -0.531 + 1.015x log10
(copies/mL) with the previous real-time PCR test. The
95% CI for the estimated intercept was -0.92, -0.14. The
95% CI for the estimated slope was: 0.95, 1.08 (data not
shown).
Comparison of the ultra sensitive RTQ-PCR with TaqMan
Among the 94 samples tested with the TaqMan test, 85
(90.4%) were found to be above the threshold of detec-
tion, while a higher sensitivity was observed for the ultra
sensitive RTQ-PCR method (89 samples tested positive
out of 94, 94.7%). As shown in Table 3, 83 (88.3%) sam-
ples were detectable by both methods, while 6 (6.4%)
and 2 (2.1%) samples were tested positive only by the
ultra sensitive RTQ-PCR and the TaqMan test,
Table 2 Efficiency of the ultra sensitive RTQ-PCR and HBV
Procleix Ultrio discriminatory HBV tests (dHBV) on 27
samples collected from 22 individuals with occult
Hepatitis B
Ultra sensitive RTQ-PCR dHBV
+ (n. %) - (n. %) Total
+ 14 (77.8%) 4 (22.2%) 18 (66.7%)
- 5 (55.6%) 4 (44.4%) 9 (33.3%)
Total 19 (70.4%) 8 (29.3%) 27 (100%)
Figure 1 Calibration of the HBV-DNA values using the ultra-sensitive RTQ-PCR assay versus the WHO International Units. Correlation
plot of the expected (log10 HBV-DNA IU/mL) versus the estimated values by ultra sensitive RTQ-PCR (log10 HBV-DNA copies/mL) tested on 5
serial concentrations of the WHO International standard ranging between 2 × 102 -2 × 106 IU/mL by using the plasmid DNA as a standard.
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respectively. These qualitative findings suggest that the
new version of the in-house assay performed equally
well as the commercially available TaqMan Test (McNe-
mar’s p = 0.157). The in-house assay found positive six
samples (ranging from 1.37 to 1.83 log10 IU/mL) with
undetectable viral load levels with COBAS TaqMan
HBV Test, while it did not quantify two samples (with
viral load levels 1.08 and 1.77 log10 IU/mL, respectively).
Fig. 2 shows the scatter plot of log10 HBV-DNA IU/
mL determined by the ultra sensitive RTQ-PCR and the
TaqMan assays, using specimens with detectable HBV-
DNA by both assays (N = 83). The results of the two
assays were linearly correlated (r = 0.979, p < 0.001).
The fitted regression line differs significantly from the
line of equality and was described by the equation: log10
(TaqMan, IU/mL) = -0.457 + 0.987 log10 (ultra sensitive
RTQ-PCR, IU/mL) (joint test of intercept = 0 and slope
= 1: p < 0.001).
Discussion
Sensitive detection and quantification of HBV-DNA is
essential for monitoring response to therapy and, also,
for assessment of occult HBV infection. Therefore,
ultra-sensitive assays for HBV-DNA quantification are
needed in clinical practice.
In the current study, we describe the characteristics of
a new ultra sensitive in-house RTQ-PCR performed in a
LightCycler® 2.0 instrument (Roche, Molecular Biochem-
icals, Mannheim, Germany). The new assay showed
improved sensitivity of 22 and 8 IU/mL as 95% and 50%
detection end-points, respectively, versus the 94 IU/mL
(250 copies/mL) of the previously reported quantitative
test [12]. The sensitivity of the assay was improved
mainly because of a larger volume of HBV-DNA used in
ultra sensitive RTQ-PCR, extracted also from a larger
volume of serum/plasma. Additionally, the new assay
was carried out in the LightCycler® 2.0 that shows
improved performance than the LightCycler® 1.0. We
should note that the sensitivity of the assay can be
potentially improved by using a larger than 0.5 mL
volume of plasma, after a concentration step performed
before the standard procedure. Moreover, the plasmid
standard calibrated against the WHO 1st International
standard, thus suggesting that the HBV-DNA values are
reported in the international format (IU/mL).
Importantly, the ultra sensitive RTQ-PCR performed
equally well as the qualitative dHBV assay tested on
low-titer HBV-DNA samples collected from individuals
with occult Hepatitis B. These findings are in accor-
dance with the previously reported 95% detection limit
of the dHBV, 19 IU/mL [16], which is almost identical
to the 95% detection limit (22 IU/mL) of the ultra sensi-
tive RTQ-PCR assay. These findings suggest that the
ultra sensitive RTQ-PCR assay is equally reliable as the
Table 3 Efficiency of the ultra sensitive RTQ-PCR and
COBAS TaqMan Test on 94 randomly selected samples
with Hepatitis B
Ultra sensitive RTQ-PCR COBAS TaqMan Test
+ (n. %) - (n. %) Total
+ 83 (88.3%) 6 (6.4%) 89 (94.7%)
- 2 (2.1%) 3 (3.2%) 5 (5.3%)
Total 85 (90.4%) 9 (9.6) 94 (100%)
Figure 2 Comparison of the HBV-DNA values estimated using COBAS TaqMan Test and ultra-sensitive RTQ-PCR. Correlation plot of log10
HBV-DNA IU/mL as determined by ultra sensitive RTQ-PCR and COBAS TaqMan Test in 83 specimens detectable by both assays. Superimposed
the regression fitted line (discontinuous line) and the line of equality (diagonal constant line).
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dHBV for detecting HBV-DNA in low-titer samples as
those collected from patients with occult Hepatitis B.
We should note however that the ultra sensitive RTQ-
PCR is a quantitative test and therefore it shouldn’t be
used for diagnostic purposes.
The HBV-DNA quantified values between the ultra
sensitive RTQ-PCR and the previously reported HBV-
DNA test correlated very well, suggesting that the new
version of the test can be utilized in occasions in which
the original test was used. Furthermore, the ultra sensi-
tive RTQ-PCR was found to be highly correlated with
commercial available COBAS TaqMan HBV Test (r =
0.979, p < 0.001).
Conclusion
In the era of highly potent antivirals (e.g. tenofovir,
entecavir) approved for the treatment of chronic Hepati-
tis B, it is of crucial importance to utilize highly sensi-
tive assays for detecting and quantifying HBV-DNA. We
report the new ultra sensitive assay, using molecular
beacon as a detection system, with remarkable analytical
and clinical sensitivity, calibrated against the WHO 1st
International standard.
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